MYGN

4.59

2.00% 0.09

Dopo l'orario di chiusura: 4.59

Myriad Genetics Inc (MYGN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché MYGN Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$4.50

Aprire:

$4.53

Volume 24 ore:

853.94K

Relative Volume:

0.54

Capitalizzazione di mercato:

$429.20M

Reddito:

$824.50M

Utile/perdita netta:

$-365.90M

Rapporto P/E:

-1.1611

EPS:

-3.9531

Flusso di cassa netto:

$-25.60M

1 W Prestazione:

-1.92%

1M Prestazione:

-0.43%

6M Prestazione:

-40.62%

1 anno Prestazione:

-48.08%

Intervallo 1D:

$4.51

$4.695

Intervallo di 1 settimana:

$4.20

$4.81

Portata 52W:

$3.76

$8.97

Myriad Genetics Inc Stock (MYGN) Company Profile

Nome

Myriad Genetics Inc

Settore

Healthcare (1116)

Industria

Diagnostics & Research (52)

Telefono

801-584-3600

Indirizzo

322 NORTH 2200 WEST, SALT LAKE CITY, UT

Dipendente

2,700

Cinguettio

@myriadgenetics

Prossima data di guadagno

2025-02-24

Ultimi documenti SEC

MYGN's Discussions on Twitter

Compare MYGN vs TMO, DHR, IDXX, A, WAT

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
MYGN Myriad Genetics Inc	4.59	420.79M	824.50M	-365.90M	-25.60M	-3.9531
TMO Thermo Fisher Scientific Inc	494.54	182.60B	44.56B	6.72B	6.29B	17.74
DHR Danaher Corp	190.79	134.18B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	564.66	44.63B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	114.54	32.21B	7.07B	1.29B	993.00M	4.5355
WAT Waters Corp	299.89	29.21B	3.17B	642.63M	516.49M	10.77

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-05-21	Downgrade	Scotiabank	Sector Outperform → Sector Perform
2025-05-08	Downgrade	Wolfe Research	Outperform → Peer Perform
2025-05-07	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-04-09	Downgrade	Guggenheim	Buy → Neutral
2025-03-12	Aggiornamento	Piper Sandler	Neutral → Overweight
2025-02-12	Iniziato	Craig Hallum	Buy
2024-12-10	Iniziato	UBS	Neutral
2024-12-09	Downgrade	Leerink Partners	Outperform → Market Perform
2024-09-19	Iniziato	Morgan Stanley	Equal-Weight
2024-08-28	Iniziato	Wells Fargo	Overweight
2024-06-27	Iniziato	Scotiabank	Sector Outperform
2024-06-03	Ripresa	Jefferies	Underperform
2024-05-08	Aggiornamento	Leerink Partners	Market Perform → Outperform
2023-12-21	Ripresa	Piper Sandler	Neutral
2023-12-19	Iniziato	Wells Fargo	Equal Weight
2023-12-14	Iniziato	Guggenheim	Buy
2023-12-13	Iniziato	Wolfe Research	Outperform
2023-07-05	Ripresa	JP Morgan	Underweight
2023-05-23	Aggiornamento	Goldman	Sell → Buy
2023-01-18	Aggiornamento	Raymond James	Mkt Perform → Outperform
2022-10-06	Iniziato	Stephens	Equal-Weight
2021-10-15	Ripresa	Cowen	Market Perform
2021-06-15	Iniziato	Raymond James	Mkt Perform
2021-06-03	Iniziato	Goldman	Sell
2019-09-26	Downgrade	BofA/Merrill	Neutral → Underperform
2019-08-14	Downgrade	Piper Jaffray	Overweight → Neutral
2019-08-02	Aggiornamento	BofA/Merrill	Underperform → Neutral
2019-08-01	Aggiornamento	Barclays	Underweight → Equal Weight
2019-07-29	Downgrade	Needham	Strong Buy → Hold
2019-07-09	Downgrade	Cowen	Outperform → Market Perform
2019-03-12	Reiterato	Needham	Strong Buy
2019-01-03	Iniziato	Needham	Strong Buy
2018-11-30	Aggiornamento	Goldman	Sell → Neutral
2018-10-10	Aggiornamento	Piper Jaffray	Neutral → Overweight
2018-07-11	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2018-03-21	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2018-01-29	Iniziato	Goldman	Sell
2018-01-22	Reiterato	Barclays	Equal Weight
2018-01-05	Iniziato	BTIG Research	Buy
2017-10-02	Ripresa	Leerink Partners	Mkt Perform
2017-08-09	Reiterato	Barclays	Equal Weight
2017-02-08	Aggiornamento	Ladenburg Thalmann	Sell → Neutral
2017-01-18	Iniziato	Deutsche Bank	Sell
2016-10-10	Downgrade	Ladenburg Thalmann	Neutral → Sell

Mostra tutto

Myriad Genetics Inc Borsa (MYGN) Ultime notizie

Mar 31, 2026

Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know - Yahoo Finance

Mar 27, 2026

Vanguard (MYGN) amendment shows 0 shares; subsidiaries disaggregate holdings - Stock Titan

Mar 27, 2026

Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat

Mar 27, 2026

Mar 26, 2026

MYGN Stock Price, Quote & Chart | MYRIAD GENETICS INC (NASDAQ:MYGN) - chartmill.com

Mar 26, 2026

Mar 25, 2026

Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Mar 25, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - natlawreview.com

Mar 25, 2026

Mar 24, 2026

Myriad Genetics launches Prequel Prenatal Screen using AMPLIFY technology for early chromosomal risk detection - Traders Union

Mar 24, 2026

Mar 23, 2026

Myriad Genetics (MYGN) CSO has shares withheld to cover RSU taxes - Stock Titan

Mar 23, 2026

Myriad Genetics (MYGN) COO has 2,055 shares withheld to cover taxes - Stock Titan

Mar 23, 2026

Myriad Genetics (MYGN) CFO uses 549 shares for RSU tax withholding - Stock Titan

Mar 23, 2026

Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus

Mar 23, 2026

Mar 22, 2026

Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P 600 - marketscreener.com

Mar 22, 2026

Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P Composite 1500 - marketscreener.com

Mar 22, 2026

Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P 600 Health Care - marketscreener.com

Mar 22, 2026

Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P 1000 - marketscreener.com

Mar 22, 2026

Mar 21, 2026

If You Invested $1,000 in Myriad Genetics (MYGN) - Stock Titan

Mar 21, 2026

Gene Patent Showdown For Myriad Comes to a Head - Yahoo

Mar 21, 2026

MYGN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Mar 21, 2026

Mar 19, 2026

Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term - Yahoo Finance

Mar 19, 2026

Mar 18, 2026

Prequel Prenatal Screen enables providers to act on uncertain results, Myriad Genetics asserts - Traders Union

Mar 18, 2026

Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Mar 18, 2026

Myriad Genetics (MYGN) Q4 earnings and revenues surpass estimates - MSN

Mar 18, 2026

Myriad Genetics receives FDA approval for ovarian cancer test By Investing.com - za.investing.com

Mar 18, 2026

Mar 17, 2026

FDA Approves Myriad Genetics' MyChoice CDx Test for Advanced Ova - gurufocus.com

Mar 17, 2026

Myriad Genetics receives FDA approval for ovarian cancer test - Investing.com

Mar 17, 2026

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer - The Manila Times

Mar 17, 2026

Portfolio Update: Can Myriad Genetics Inc maintain its current growth rate2026 Trading Volume Trends & Community Driven Trade Alerts - baoquankhu1.vn

Mar 17, 2026

Mar 16, 2026

Myriad Genetics (MYGN) CTO has shares withheld to cover taxes - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) CFO granted 206,186 RSUs, 4,752 shares withheld - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) grants 173196 RSUs, withholds 14683 shares for tax - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) CSO gets 173,196 RSUs, withholds 37,799 shares - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) CLO granted 195,876 RSUs and has shares withheld - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) Chief Commercial Officer granted 226,804 RSUs - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) COO receives RSU grant, shares withheld for tax - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) CEO gets 618,557 RSUs, 47,120 shares withheld - Stock Titan

Mar 16, 2026

Myriad Genetics Inc Stock (ISIN: US62855J1043) Eyes Precision Medicine Growth Amid Margin Expansion - AD HOC NEWS

Mar 16, 2026

Mar 15, 2026